EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical application of a modified platelet desialylation test for mechanistic characterization of platelet transfusion refractoriness

Karen Ziza, Thamy Silva, Mateus Domentino, Marina Conrado, João Oliveira, Elyse Moritz, Akemi Chiba, Vanderson Rocha, Alfredo Mendrone-Junior, José Bordin, Langhi Dante iD, Carla Dinardo

Transfusion · 2026-08 · 66 (8) · 1520-1535

DOI: 10.1111/trf.70246 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfusion, online erschienen am 29.04.2026. Verfasst von Karen Ziza und 11 weiteren Autor:innen. Beteiligte Einrichtung: Fundação Pró-Sangue, Hemocentro de São Paulo, São Paulo, São Paulo, Brazil. Hauptthemen laut MEDLINE: Platelet Transfusion, Blood Platelets, Isoantibodies, Thrombocytopenia. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Platelet transfusion refractoriness (PTR) is a major challenge in transfusion medicine and may result from both immune and non‐immune mechanisms. Although alloantibodies are well‐established contributors, Fc‐independent pathways such as platelet desialylation have emerged as alternative mechanisms of clearance. Study Design and Methods In this prospective diagnostic study, 81 patients with suspected PTR were evaluated using an integrated approach combining the platelet immunofluorescence test (PIFT) to detect antibody‐mediated refractoriness and a modified platelet desialylation test (PDT) to assess Fc‐independent clearance. Demographic, clinical, and laboratory variables were analyzed using non‐parametric tests, including Mann–Whitney U , Kruskal–Wallis, and binomial tests.

Results

The cohort exhibited severe thrombocytopenia and diverse clinical profiles. PIFT detected platelet‐bound antibodies in 63/81 cases (78%), while PDT identified desialylation in 41/81 patients (50%). PIFT positivity was similar between PDT‐positive (80.5%) and PDT‐negative (76.9%) groups, with no significant association ( χ 2 = 0.15, p = .69). Although mean fluorescence intensity (MFI) varied across diagnostic categories, no significant differences were observed ( p = .3095). Fever was the only clinical variable significantly associated with reduced desialylation (median MFI 401 vs. 1328.3; p = .0109), while splenomegaly, infection, antifungal use, and bleeding had no significant effects. PDT status was not significantly associated with the number of pooled platelet transfusions ( p = .391) or apheresis procedures ( p = .515), indicating that desialylation alone does not predict transfusion demand.

Discussion

PTR occurs both independently and in parallel with antibody‐mediated pathways. The combined PIFT‐modified PDT approach improves mechanistic characterization and enhances diagnostic accuracy, in cases of platelet refractoriness of immune and non‐immune etiology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet TransfusionBlood PlateletsIsoantibodiesThrombocytopeniaHumansFemaleMaleProspective StudiesMiddle AgedAgedAdult

Stichwörter der Autor:innen

desialylationplatelet refractorinessplatelet transfusion

Substanzen

Isoantibodies

Autor:innen und Institutionen

  • Fundação Pró-Sangue, Hemocentro de São Paulo, São Paulo, São Paulo, Brazil.
  • Department of Hematology, Universidade Federal de São Paulo (UNIFESP), São Paulo, São Paulo, Brazil.
  • Institute of Health Sciences, Universidade Paulista, São Paulo, São Paulo, Brazil.
  • Department of Hematology, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, São Paulo, Brazil.
  • Churchill Hospital, NHS BT, Oxford University, Oxford, UK.

ORCID-Profile: Langhi Dante

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico

Zitieren

APA

Ziza, K., Silva, T., Domentino, M., Conrado, M., Oliveira, J., Moritz, E., Chiba, A., Rocha, V., Mendrone-Junior, A., Bordin, J., Dante, L., & Dinardo, C. (2026). Clinical application of a modified platelet desialylation test for mechanistic characterization of platelet transfusion refractoriness. Transfusion, 66(8), 1520-1535. https://doi.org/10.1111/trf.70246

Vancouver

Ziza K, Silva T, Domentino M, Conrado M, Oliveira J, Moritz E, et al. Clinical application of a modified platelet desialylation test for mechanistic characterization of platelet transfusion refractoriness. Transfusion. 2026;66(8):1520-1535. doi:10.1111/trf.70246

BibTeX
@article{Ziza2026,
  author = {Ziza, Karen and Silva, Thamy and Domentino, Mateus and Conrado, Marina and Oliveira, João and Moritz, Elyse and Chiba, Akemi and Rocha, Vanderson and Mendrone-Junior, Alfredo and Bordin, José and Dante, Langhi and Dinardo, Carla},
  title = {Clinical application of a modified platelet desialylation test for mechanistic characterization of platelet transfusion refractoriness},
  journal = {Transfusion},
  year = {2026},
  volume = {66},
  number = {8},
  pages = {1520--1535},
  doi = {10.1111/trf.70246}
}
Kostenlos starten →